BRPI0810461A2 - Combinação de drogas e seu uso no tratamento de perda muscular - Google Patents

Combinação de drogas e seu uso no tratamento de perda muscular

Info

Publication number
BRPI0810461A2
BRPI0810461A2 BRPI0810461-1A2A BRPI0810461A BRPI0810461A2 BR PI0810461 A2 BRPI0810461 A2 BR PI0810461A2 BR PI0810461 A BRPI0810461 A BR PI0810461A BR PI0810461 A2 BRPI0810461 A2 BR PI0810461A2
Authority
BR
Brazil
Prior art keywords
drug combination
loss treatment
muscular
muscular loss
treatment
Prior art date
Application number
BRPI0810461-1A2A
Other languages
English (en)
Inventor
Julian Clive Gilbert
Robert William Gristwood
Original Assignee
Acacia Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0707930A external-priority patent/GB0707930D0/en
Priority claimed from GB0707931A external-priority patent/GB0707931D0/en
Priority claimed from GB0710101A external-priority patent/GB0710101D0/en
Application filed by Acacia Pharma Ltd filed Critical Acacia Pharma Ltd
Publication of BRPI0810461A2 publication Critical patent/BRPI0810461A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
BRPI0810461-1A2A 2007-04-24 2008-04-24 Combinação de drogas e seu uso no tratamento de perda muscular BRPI0810461A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0707930A GB0707930D0 (en) 2007-04-24 2007-04-24 New therapeutic use
GB0707931A GB0707931D0 (en) 2007-04-24 2007-04-24 New Therapeutic use
GB0710101A GB0710101D0 (en) 2007-05-25 2007-05-25 New Therapeutic use
PCT/GB2008/001452 WO2008129308A2 (en) 2007-04-24 2008-04-24 Drug combination and its use in the treatment of muscle loss

Publications (1)

Publication Number Publication Date
BRPI0810461A2 true BRPI0810461A2 (pt) 2014-10-14

Family

ID=39639100

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0810461-1A2A BRPI0810461A2 (pt) 2007-04-24 2008-04-24 Combinação de drogas e seu uso no tratamento de perda muscular

Country Status (16)

Country Link
US (1) US8653052B2 (pt)
EP (1) EP2155180B1 (pt)
JP (1) JP5627452B2 (pt)
KR (1) KR101546977B1 (pt)
CN (2) CN101730547A (pt)
AU (1) AU2008240379B2 (pt)
BR (1) BRPI0810461A2 (pt)
CA (1) CA2721739C (pt)
DK (1) DK2155180T3 (pt)
EA (1) EA018918B1 (pt)
ES (1) ES2592289T3 (pt)
HK (1) HK1202262A1 (pt)
IL (1) IL201426A (pt)
MX (1) MX2009011294A (pt)
NZ (1) NZ580975A (pt)
WO (1) WO2008129308A2 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1121111B1 (en) 1998-10-15 2010-02-10 Imperial Innovations Limited Compounds for the treatment of weight loss
WO2007011743A2 (en) 2005-07-14 2007-01-25 Lipothera, Inc. Sustained release enhanced lipolytic formulation for regional adipose tissue treatment
GB0624282D0 (en) 2006-12-05 2007-01-10 Cavalla David Treatment of cachexia
US9597531B2 (en) 2010-11-24 2017-03-21 Neothetics, Inc. Selective, lipophilic, and long-acting beta agonist monotherapeutic formulations and methods for the cosmetic treatment of adiposity and contour bulging
US9873695B2 (en) * 2014-08-05 2018-01-23 Raqualia Pharma Inc. Serine derivatives as ghrelin receptor agonists

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0308157B1 (en) 1987-09-15 1997-02-26 The Rowett Research Institute Therapeutic applications of beta-adrenergic agonists
DK1494649T3 (da) * 2002-04-12 2012-04-10 Alkermes Pharma Ireland Ltd Nanopartikel-megestrolformuleringer
US7101576B2 (en) * 2002-04-12 2006-09-05 Elan Pharma International Limited Nanoparticulate megestrol formulations
ES2245612B1 (es) * 2004-06-29 2007-08-16 Universidad De Barcelona Nuevo uso terapeutico del formoterol.
JP2009526087A (ja) * 2005-12-22 2009-07-16 アナボレックス， インコーポレイテッド 悪液質の予防および処置のための組成物および方法
US7947579B2 (en) * 2006-02-13 2011-05-24 Stc.Unm Method of making dense, conformal, ultra-thin cap layers for nanoporous low-k ILD by plasma assisted atomic layer deposition

Also Published As

Publication number Publication date
KR20100017205A (ko) 2010-02-16
AU2008240379B2 (en) 2012-10-04
EA018918B1 (ru) 2013-11-29
MX2009011294A (es) 2010-01-29
JP5627452B2 (ja) 2014-11-19
KR101546977B1 (ko) 2015-08-24
ES2592289T3 (es) 2016-11-29
JP2010525044A (ja) 2010-07-22
HK1202262A1 (en) 2015-09-25
EP2155180A2 (en) 2010-02-24
EP2155180B1 (en) 2016-07-13
US20100130456A1 (en) 2010-05-27
DK2155180T3 (en) 2016-09-12
CA2721739C (en) 2016-08-23
IL201426A (en) 2016-09-29
WO2008129308A2 (en) 2008-10-30
IL201426A0 (en) 2010-05-31
WO2008129308A3 (en) 2009-12-17
NZ580975A (en) 2012-10-26
CN104306381A (zh) 2015-01-28
CA2721739A1 (en) 2008-10-30
AU2008240379A1 (en) 2008-10-30
US8653052B2 (en) 2014-02-18
EA200970957A1 (ru) 2010-04-30
CN101730547A (zh) 2010-06-09

Similar Documents

Publication Publication Date Title
BRPI0719345A2 (pt) Di-hidroimidazóis substituídos e seu uso no tratamento de tumores.
BRPI0814267A2 (pt) Agentes citotóxicos compreendendo novos derivados de tomaicmicina e o seu uso terapêutico.
BRPI0815204A2 (pt) Dispositivo de administração fecal e utilização do dispositivo
IL236831A0 (en) Expression of micro rna in peripheral narrow blood vessels in the human body, and their uses
BRPI1008045A2 (pt) derivados de aminotetralina, composições farmacêuticas contendo-os, e seu uso em terapia
CR10769A (es) Improvements in and relating to drive mechanisms suitable for use in drug delicery devices
ATE488227T1 (de) Feste zubereitung mit alogliptin und pioglitazon
GB0523576D0 (en) Drug composition and its use in therapy
BR112012000370A2 (pt) derivados de 1,2,4-tiazolidin-3-ona e seus usos no tratamento de câncer
BRPI0813263A2 (pt) Oxazolidinonas substituídas e seu uso
BRPI0819519A2 (pt) Análogos de triarilmetano e seus usos no tratamento de cânceres.
BRPI0818766A2 (pt) N-fenil-pirrolidinilmetilpirrolidinamidas substituídas e uso terapêutico das mesmas
BRPI0810475A2 (pt) uso de dimiracetam no tratamento de dor crônica
BRPI0810461A2 (pt) Combinação de drogas e seu uso no tratamento de perda muscular
IL219768A0 (en) Drug combination with thebromine and its use in therapy
BRPI0714318A2 (pt) Utilização de 2-benzoil-imidazopiridinas em terapêutica
BRPI0909096A2 (pt) uso de conjugados de interleicna-1 no tratamento de diabetes
DK2310383T3 (da) 2-oxo-alkyl-1-piperazin-2-onderivater, fremstilling deraf og terapeutisk anvendelse deraf
DK2293846T3 (da) Depsipeptider og deres terapeutiske anvendelse
ZA200903865B (en) Pyrrole derivatives, preparation and use of the same in therapy
IL219769A0 (en) Drug combination with theromine and its use in therapy
DK2370046T3 (da) Lægemiddeldispenser og anvendelse heraf
GB2463584B (en) Carbohydrate-lipid constructs and their use in preventing or treating viral infection
HK1139671A1 (en) Azabicycloalkane derivatives, preparation thereof and use thereof in therapy
BRPI0719997A2 (pt) Uso de epotilonas no tratamento de osteoporose e doenças relacionadas

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2515 DE 19-03-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]